RhumbLine Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $245K | Sell |
65,958
-4,845
| -7% | -$18K | ﹤0.01% | 3114 |
|
|
2025
Q1 | $229K | Sell |
70,803
-2,628
| -4% | -$8.49K | ﹤0.01% | 3040 |
|
|
2024
Q4 | $409K | Buy |
73,431
+3,675
| +5% | +$20.5K | ﹤0.01% | 2794 |
|
|
2024
Q3 | $754K | Sell |
69,756
-3,177
| -4% | -$34.3K | ﹤0.01% | 2422 |
|
|
2024
Q2 | $1.53M | Buy |
72,933
+9,062
| +14% | +$190K | ﹤0.01% | 2023 |
|
|
2024
Q1 | $2.03M | Buy |
63,871
+3,950
| +7% | +$126K | ﹤0.01% | 1909 |
|
|
2023
Q4 | $1.21M | Buy |
59,921
+1,472
| +3% | +$29.8K | ﹤0.01% | 2154 |
|
|
2023
Q3 | $744K | Buy |
58,449
+9,461
| +19% | +$120K | ﹤0.01% | 2372 |
|
|
2023
Q2 | $885K | Buy |
48,988
+1,487
| +3% | +$26.9K | ﹤0.01% | 2360 |
|
|
2023
Q1 | $817K | Buy |
47,501
+58
| +0.1% | +$998 | ﹤0.01% | 2219 |
|
|
2022
Q4 | $1.05M | Buy |
47,443
+2,070
| +5% | +$46K | ﹤0.01% | 2106 |
|
|
2022
Q3 | $365K | Buy |
45,373
+3,788
| +9% | +$30.5K | ﹤0.01% | 2637 |
|
|
2022
Q2 | $290K | Buy |
41,585
+6,488
| +18% | +$45.2K | ﹤0.01% | 2773 |
|
|
2022
Q1 | $531K | Buy |
35,097
+4,382
| +14% | +$66.3K | ﹤0.01% | 2400 |
|
|
2021
Q4 | $674K | Buy |
30,715
+6,177
| +25% | +$136K | ﹤0.01% | 2384 |
|
|
2021
Q3 | $662K | Buy |
24,538
+15,031
| +158% | +$406K | ﹤0.01% | 2425 |
|
|
2021
Q2 | $229K | Buy |
9,507
+3,651
| +62% | +$87.9K | ﹤0.01% | 2887 |
|
|
2021
Q1 | $254K | Buy |
+5,856
| New | +$254K | ﹤0.01% | 2755 |
|